Rebif®
Rebif® (interferon beta-1a) is a disease modifying drug (DMD) used to treat relapsing forms of multiple sclerosis (MS). It
is similar to the interferon beta protein produced by the human body.
Rebif has been approved for the treatment of relapsing forms of MS in over 80 countries worldwide.
The reformulated version of Rebif® has been approved in the European Union, Switzerland, Australia, Canada and many other
regions. It is under regulatory review in other countries including the United States.
| Disclaimer |
|
The information in this section is intended for Healthcare Professionals only. US residents should consult the EMD Serono, Inc. for information on products approved for sales in the United States of America. |
